Jul 16
Current report
8-K
Charter or bylaw amendment, or fiscal year change
TCRT · Alaunos Therapeutics, Inc. · Documents
$1.74
-0.10 (-5.43%)
At close · Nov 6
Return incl. dividend (before tax)
Q1 2023 earnings call transcript
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements which raises substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$4.42M
Shares
2.54M
Volume · Nov 6
101.46K
Avg daily vol (3M)
7.43M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2024
Jun 21
Current report
8-K
Events of Jun 19
Change of auditor
Jun 12
Current report
8-K
Events of Jun 6
Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Shareholder vote results
May 15
Quarterly report
10-Q
FY2024 Q1, ended Mar 31
Quarterly report for FY2024 Q1
Revenue $1000
Net loss $1.68M
Diluted EPS -$0.11
Apr 26
Proxy statement
DEF 14A
Meeting Jun 6, 2024
Proxy statement
Apr 26
Annual report to holders
ARS
Annual report to holders
Apr 26
Proxy statement
DEFA14A
Proxy statement
Apr 15
Proxy statement
PRE 14A
Meeting Jun 6, 2024
Proxy statement
Apr 1
Annual report
10-K
FY2023, ended Dec 31
Annual report for FY2023
Revenue $5000
▼ 99.8%
Net loss $35.14M
Diluted EPS -$2.20
Feb 22
Current report
8-K
Events of Feb 15
Director or officer change, or executive pay
Feb 20
Current report
8-K
Events of Feb 16
Other events
Feb 1
Current report
8-K
Events of Jan 31
Charter or bylaw amendment, or fiscal year change
Jan 29
Current report
8-K
Other events
Jan 22
Current report
8-K
Events of Jan 20
Director or officer change, or executive pay
Jan 2
Current report
8-K
Events of Dec 29
Director or officer change, or executive pay, Regulation FD disclosure
2023
Dec 28
Current report
8-K
Events of Dec 22
Director or officer change, or executive pay
Dec 22
Current report
8-K
Events of Dec 18
Director or officer change, or executive pay
Nov 15
Current report
8-K
Events of Nov 14
Director or officer change, or executive pay
Nov 14
Current report
8-K
Events of Nov 8
Financial results, Delisting notice or listing transfer
Nov 14
Quarterly report
10-Q
FY2023 Q3, ended Sep 30
Quarterly report for FY2023 Q3
Revenue $0
Net loss $8.48M
Diluted EPS -$0.04
Sep 28
Current report
8-K
Events of Sep 22
Director or officer change, or executive pay
Aug 14
Current report
8-K
Financial results
Aug 14
Quarterly report
10-Q
FY2023 Q2, ended Jun 30
Quarterly report for FY2023 Q2
Revenue $4000
Net loss $8.77M
Diluted EPS -$0.04
Jul 5
Current report
8-K
Delisting notice or listing transfer
Jun 12
Current report
8-K
Events of Jun 6
Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Shareholder vote results
May 10
Earnings call
Q1 2023 earnings call
May 10
Current report
8-K
Financial results
May 10
Quarterly report
10-Q
FY2023 Q1, ended Mar 31
Quarterly report for FY2023 Q1
Net loss $10.05M
Diluted EPS -$0.04
Apr 25
Proxy statement
DEF 14A
Meeting Jun 6, 2023
Proxy statement
Apr 25
Proxy statement
DEFA14A
Proxy statement
Apr 14
Proxy statement
PRE 14A
Meeting Jun 6, 2023
Proxy statement
Apr 4
Current report
8-K
Events of Apr 3
Entered into a material agreement
Apr 3
Current report
8-K
Events of Mar 30
Entered into a material agreement
Mar 30
Current report
8-K
Events of Mar 29
Director or officer change, or executive pay
Mar 7
Earnings call
Q4 2022 earnings call
Mar 7
Current report
8-K
Financial results
Mar 7
Annual report
10-K
FY2022, ended Dec 31
Annual report for FY2022
Revenue $2.92M
▲ 634.2%
Net loss $37.73M
Diluted EPS -$0.17
Jan 9
Current report
8-K
Regulation FD disclosure, Other events
Jan 4
Current report
8-K
Delisting notice or listing transfer
2022
Nov 30
Current report
8-K
Events of Nov 28
Entered into a material agreement, Other events
Nov 14
Earnings call
Q3 2022 earnings call
Nov 14
Current report
8-K
Financial results, Regulation FD disclosure
Nov 14
Quarterly report
10-Q
FY2022 Q3, ended Sep 30
Quarterly report for FY2022 Q3
Revenue $2.91M
▲ 631.4%
Net loss $8.85M
Diluted EPS -$0.04
Nov 7
Current report
8-K
Regulation FD disclosure
Sep 30
Current report
8-K
Other events
Sep 21
Current report
8-K
Regulation FD disclosure
Sep 6
Current report
8-K
Other events
Aug 31
Registration statement
S-3/A
Registration statement
Aug 24
Current report
8-K
Regulation FD disclosure
Aug 15
Earnings call
Q2 2022 earnings call
Showing 51–100 of 194 documents
Key facts
CIK
1107421
CUSIP
98973P309
13F (30d)
18 filings
11 filers
Visit website
Investor relations